Clinical Trials Logo

Hyperactivity clinical trials

View clinical trials related to Hyperactivity.

Filter by:
  • None
  • Page 1

NCT ID: NCT05618470 Recruiting - Dry Eye Syndromes Clinical Trials

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Start date: January 12, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

NCT ID: NCT05219370 Terminated - ADHD Clinical Trials

Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD

Start date: July 31, 2022
Phase: Phase 2
Study type: Interventional

ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood. Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and amphetamines) and non-stimulants (such as atomoxetine, guanfacine and clonidine) but some persons cannot tolerate their secondary effects or find them non-effective. In the last decade, medical cannabis products have been researched as possible treatment for neurological and mental diseases such as: Post trauma disorder (PTD), autism (ASD), epilepsy, fibromyalgia (FM) and more. Data on the effects of cannabidiol rich cannabis extract use for ADHD seems promising but is still limited. The aim of this study is to investigate if oral cannabinoids given to adults with ADHD affect the symptoms of the disorder. The main objectives of the study are: 1) to characterize the effects of treatment with cannabis oil on symptoms of ADHD; 2) to compare safety and efficacy of cannabis oil products with different CBD,Cannabidivarin (CBDV), cannabigerol (CBG) and THC ratio; 3) and to measure endocannabinoids, THC and CBD and metabolites levels in the blood of the participants. In this study, participants diagnosed with ADHD will be treated with canabidiol-rich cannabis oil and will follow up weekly during approx.1 month (the study period). Blood tests will be performed before and after treatment. Blood tests include blood count, blood chemistry, hormones profile, phyto- and endo- cannabinoids and their metabolites. Test of Variables of Attention test (TOVA) will be administrated before and after treatment

NCT ID: NCT04286542 Active, not recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

Rhinitis, or inflammation of the nasal mucosa, can present with nasal obstruction, nasal discharge, itch or sneezing. If the sinusal mucosa is involved as well, it is called rhinosinusitis and facial pain or loss of smell is possible. Several causes are known, such as an underlying allergy ("allergic rhinitis", AR). If at least 2 symptoms are present for at least 12 weeks, it is called "chronic rhinosinusitis" (CRS). Up to 2/3 of the AR and CRS patients have symptoms upon exposure to triggers such as sudden temperature changes, smoke, fragrances… a phenomenon called "nasal hyperreactivity" (NHR). It is currently not clear why some patients suffer NHR while others do not. In this study, the investigators want to identify the mediators associated with NHR in patients with allergic rhinitis, chronic rhinosinusitis and healthy control subjects.To do so, participants will be provoked with cold, dry air in order to objectively diagnose NHR. Before and after provocation, the peak nasal inspiratory flow will be measured and samples will be collected (nasal secretions, biopsies).

NCT ID: NCT04167995 Completed - Impulsivity Clinical Trials

Assessment of Probiotics Lactobacillus in the Management of Attention Deficit Hyperactive Disorder

ADHD
Start date: June 9, 2020
Phase: Early Phase 1
Study type: Interventional

ADHD is a neurodevelopmental disorder characterized by persistent symptoms of inattention and/or hyperactivity and impulsivity that are present before age 18. These symptoms must be evident across ADHD treatment is currently based on a multimodal approach with the combination of psychotherapy and pharmacotherapy, but no reliable markers of treatment response have been identified yet and 20-35% of subjects in clinical trials may have an inadequate response to the treatment The gut microbiome refers to the microbial ecosystem found in the gastrointestinal system of the human species Probiotics are a type of beneficial bacteria that improve health and facilitate intestinal microbial balance Increasing evidence suggests that the gut microbiota plays a key role in the gut-brain communication axis by influencing metabolism, inflammation, the hypothalamic-pituitary-adrenal axis, and neurotransmission multiple domains and cause Impairment in functioning in order to meet the diagnostic criteria for ADHD

NCT ID: NCT03893227 Completed - Clinical trials for Chronic Rhinosinusitis (Diagnosis)

Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation

Start date: January 22, 2019
Phase:
Study type: Observational

Rhinitis, or inflammation of the nasal mucosa, can present with nasal obstruction, nasal discharge, itch or sneezing. If the sinusal mucosa is involved as well, it is called rhinosinusitis and facial pain or loss of smell is possible. Several causes are known, such as an underlying allergy ("allergic rhinitis", AR). If at least 2 symptoms are present for at least 12 weeks, it is called "chronic rhinosinusitis" (CRS). Up to 2/3 of the AR and CRS patients have symptoms upon exposure to triggers such as sudden temperature changes, smoke, fragrances… a phenomenon called "nasal hyperreactivity" (NHR). It is currently not clear why some patients suffer NHR while others do not. In this study, the investigators want to determine the prevalence and severity of nasal hyperreactivity in patients with chronic upper airway inflammation. To this end, patients and healthy controls will be asked to fill out a questionnaire inquiring presence and severity of nasal symptoms upon exposure to particular environmental triggers.

NCT ID: NCT03218670 Recruiting - Health Behavior Clinical Trials

Your Health in On Click

TS1C
Start date: September 1, 2009
Phase: N/A
Study type: Observational

A health education program was provided to higher education students aged between 18 and 25 years. Students were recruited either by posters and leaflets on campus, or during their mandatory medical survey at the University Medical Department. The objectives are to assess health behavior risk among college student : e.g eating disorders, binge drinking, electronic cigarettes and also stress, burnout

NCT ID: NCT01694667 Completed - Clinical trials for Autism Spectrum Disorders

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

Start date: September 2012
Phase: Phase 2
Study type: Interventional

The proposed study is an internet-based, randomized, double-blind, placebo-controlled trial which will assess changes in hyperactivity in children ages five through eight with an autism spectrum disorders (ASD) and elevated levels of hyperactivity. In order to answer this question, this study will assess changes in hyperactivity as measured by the Aberrant Behavior Checklist (ABC) in children with ASD and elevated baseline levels of hyperactivity who are randomly assigned to use 1.3 grams of omega-3 fatty acids daily compared to placebo. The overwhelming majority of study procedures, including recruitment, informed consent, assessment of inclusion and exclusion criteria, and collection of baseline and outcome measures will take place over the internet.

NCT ID: NCT01483521 Completed - Aggression Clinical Trials

Infant Psychiatry Home Visitation Program

Start date: April 2009
Phase: N/A
Study type: Interventional

This is a proposed home visitation program for families of children with externalizing behaviors who are on the wait list for psychiatric assessment at BC Children's hospital. The aim of this program is to implement and evaluate a home visitation strategy in order to support those waiting up to four months to consult a psychiatrist.